379 related articles for article (PubMed ID: 11924756)
1. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
Sikole A; Spasovski G; Zafirov D; Polenakovic M
Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
[TBL] [Abstract][Full Text] [Related]
2. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
3. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
[TBL] [Abstract][Full Text] [Related]
9. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
10. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
Abbas EE; Afioni N; Al Wakeel J; Bakr MA; Dham R; Donia A; Droubi N; Khidir E; Mathew CM; Mitwali AH; Naga S; Pingle A; Rashed A; Roshdy A; Shaheen F; Shaibani B; Shaibani FM; Shaker DS; Sheiban A; Solieman M
Transplant Proc; 2004; 36(6):1805-11. PubMed ID: 15350482
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study.
Milutinović S; Plavljanić E; Trkulja V
Fundam Clin Pharmacol; 2006 Oct; 20(5):493-502. PubMed ID: 16968421
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
14. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis.
Thitiarchakul S; Tasanarong A
J Med Assoc Thai; 2007 Apr; 90(4):636-42. PubMed ID: 17487116
[TBL] [Abstract][Full Text] [Related]
15. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
17. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
Ifudu O; Feldman J; Friedman EA
N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
[TBL] [Abstract][Full Text] [Related]
18. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
de Sousa FT; Prata MM; Barbas JV; dos Santos JP
Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
[TBL] [Abstract][Full Text] [Related]
20. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
